LBRX LB Pharmaceuticals Inc
Financings ·
The company is selling 3,577,560 shares and pre-funded warrants for up to 715,513 shares to institutional investors. The deal is expected to close on or about July 30, 2026, and the 2025 10-K filed in March 2026 shows net loss of $25.2 million for the year.
LB Pharmaceuticals agreed to sell 3,306,571 shares and pre-funded warrants for up to 1,417,107 shares to institutional investors. It plans to use the proceeds for a Phase 2 trial of LB-102 in major depressive disorder and for general corporate purposes.
The offering totals $285,000,000, and the shares are approved for listing on Nasdaq under LBRX. Proceeds to the company are $265,050,000 before expenses, and the company's lead drug has a Phase 3 trial still ahead.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $16.7 million | $51.2 million |
| Net income (loss) | -$25.2 million | -$63.1 million |
| Cash from operations | -$35.2 million | -$53.1 million |
| Cash and equivalents | $250.2 million | $23.0 million |
| Short-term investments | $45.0 million | $5.0 million |
Our latest story on this, dated Sep 12, 2025: "LB Pharmaceuticals prices IPO of 19,000,000 shares at $15.00". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 29, 2026: "LB Pharmaceuticals agrees to $150 million private placement at $34.94 a share". The story links the filing or release it is based on. Read the story.
LB Pharmaceuticals Inc trades under the ticker LBRX on NASDAQ.
LB Pharmaceuticals Inc is listed on NASDAQ.
The SEC Central Index Key (CIK) for LB Pharmaceuticals Inc is 1691082. Its filings are on SEC EDGAR.
32,259,175 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-11.
Our directory records LB Pharmaceuticals Inc under United States.
Our directory classifies LB Pharmaceuticals Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for LB Pharmaceuticals Inc is US50180M1080.
aibio.space lists LB Pharmaceuticals Inc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
LB Pharmaceuticals Inc reported a net loss of $25.2 million for the fiscal year ended Dec 31, 2025, and used $35.2 million of cash in operations, per its annual report to the SEC.
$16.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
$327.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on LB Pharmaceuticals, dated Jul 29, 2026: "LB Pharmaceuticals agrees to $150 million private placement at $34.94 a share". The company is selling 3,577,560 shares and pre-funded warrants for up to 715,513 shares to institutional investors. The deal is expected to close on or about July 30, 2026, and the 2025 10-K filed in March 2026 shows net loss of $25.2 million for the year. Source.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio